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a b s t r a c t
Genome-wide association studies have conﬁrmed the involvement of non-coding angiopoietin-like 3
(ANGPTL3) gene variants with coronary artery disease, levels of low-density lipoprotein cholesterol (LDL-
C), triglycerides and ANGPTL3 mRNA transcript. Extensive linkage disequilibrium at the locus, however,
has hindered efforts to identify the potential functional variants. Using regulatory annotations from
ENCODE, combined with functional in vivo assays such as allele-speciﬁc formaldehyde-assisted isolation
of regulatory elements, statistical approaches including eQTL/lipid colocalisation, and traditional in vitro
methodologies including electrophoretic mobility shift assay and luciferase reporter assays, variants
affecting the ANGPTL3 regulome were examined. From 253 variants associated with ANGPTL3 mRNA
expression, and/or lipid traits, 46 were located within liver regulatory elements and potentially func-
tional. One variant, rs10889352, demonstrated allele-speciﬁc effects on DNA-protein interactions, re-
porter gene expression and chromatin accessibility, in line with effects on LDL-C levels and expression of
ANGPTL3mRNA. The ANGPTL3 gene lies within DOCK7, although the variant is within non-coding regions
outside of ANGPTL3, within DOCK7, suggesting complex long-range regulatory effects on gene expression.
This study illustrates the power of combining multiple genome-wide datasets with laboratory data to
localise functional non-coding variation and provides a model for analysis of regulatory variants from
GWAS.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Genome-wide association studies (GWAS) have revealed novel
gene loci and conﬁrmed many candidate genes for numerous traits
including lipid levels and coronary artery disease (CAD) risk [1,2].
Despite the increasing number of loci associated with such traits,
identiﬁcation of functional or causal variants at each locus has not
been met with similar advances. This lack of progress is largely due
to two important characteristics: the presence of many variants in
strong linkage disequilibrium (LD) with the leading GWAS signal,
and the fact that the majority of potentially causal SNPs are located
in non-coding regions of the genome, for which in silico tools to
reliably predict SNP functionality are lacking.
A typical example of this occurs at the angiopoietin-like 3
(ANGPTL-3) gene locus, associated with triglyceride (TG) levels,
low-density lipoprotein cholesterol (LDL-C) levels, and CAD risk in
several independent GWAS [1,3,4], where the functional variant(s)
associated with these traits have not been identiﬁed. ANGPTL-3 is a
member of the angiopoietin-like proteins, a family of secreted
glycoproteins, expressed in the liver, containing a signal peptide, N-
terminal coiled coil domain and a C-terminal ﬁbrinogen-like
domain. ANGPTL-3 can inhibit lipoprotein lipase [5] and endothe-
lial lipase [6], and through the ﬁbrinogen-like domain, induce
endothelial cell adhesion and migration [7].
Abbreviations: GWAS, genome-wide association study; LDL-C, low density li-
poprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, tri-
glycerides; EMSA, electrophoretic mobility shift assay; SNP, single nucleotide
polymorphism.
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In a large meta-analysis comprising >100,000 individuals,
rs2131925, the lead SNP at the ANGPTL3 locus for TG association
(4.9 mg/dL decrease) was also associated with LDL-C levels (1.6 mg/
dL decrease) [1]. In addition to these associations with common
polymorphism, raremissense mutations in ANGPTL3 have also been
identiﬁed through exome-sequencing to be associatedwith familial
combined hypolipidemia, conﬁrming this locus as an important
mediator in lipid metabolism [8].
ANGPTL3 lies on the forward strand of chromosome 1p31 within
an intronic region of DOCK7 (located on the reverse strand).
Examining the ANGPTL3 locus, it can be seen that there are over 250
SNPs in very strong LD with the lead TG GWAS SNP that span
~250 kb and include 3 genes [1,9], ANGPTL3, DOCK7 and USP1
(Fig. 1A), leading to the strong likelihood that rs2131925 is simply
acting as a marker for the true functional variant(s). Interestingly,
SNPs at this locus show a lack of signiﬁcant association with HDL-C
(Fig. 1B), but association with LDL-C shows a similar pattern as for
TG, suggesting a common functional polymorphism (Fig. 1C and D).
One commonly employed method to identify potential causal
non-coding variants is through in silico tools, including databases
used to predict the effect of a SNP on transcription factor binding
motifs. Such methods, unfortunately, result in many false-positive
ﬁndings that are not borne out when tested in the laboratory
[10]. Functional examination of all SNPs showing association to a
trait can be undertaken in the laboratorywhere the number of SNPs
is small [11,12], although when strong LD within the association
signal results in hundreds of potentially causal variants, such
analysis is not feasible. The ENCODE and Roadmap Epigenomics
projects, however, provide additional tools that can be used to
identify non-coding regions of the genome that are likely to
harbour important regulatory features [13,14]. Where such features
also contain a genetic variant associated with an epidemiologic
trait, this may suggest potentially causality of the variant, rather
than simply a marker for the trait.
The lead SNP, rs2131925 is unlikely to represent the functional
SNP at the locus, with 92 SNPs in perfect LD, and 202 SNPs in very
strong LD (r2 > 0.8) [9]. We used data from the ENCODE Project and
Roadmap Epigenomics, in addition to epidemiological, statistical
and functional assays, to assist in the identiﬁcation of potentially
causal variants at the ANGPTL3 locus, and examined these variants
for functionality in the laboratory.
2. Materials and methods
2.1. Identiﬁcation of SNPs associated with lipid biomarkers
Variants in strong LD (r2  0.8) with the GWAS lead SNP
(rs2131925) for TG and LDL-C [14] were identiﬁed using 1000 Ge-
nomes Project CEU Caucasian population Phase 1 data (1KGP) [9].
Additionally, all variants within 500 kb from ANGPTL3 reaching
genome-wide signiﬁcance (p < 5 108) for LDL-C or TG levels using
a large-scale meta-analysis of >100,000 individuals were identiﬁed
[1] and selected for further analysis.
Fig. 1. A) Linkage disequilibrium with the lead TG GWAS SNP, rs2131925 (indicated by large diamond), at the ANGPTL3 locus. Over 200 SNPs are in strong LD at this locus (r2 > 0.8),
which span 3 genes, USP1, DOCK7 and ANGPTL3 (http://www.broadinstitute.org/mpg/snap/ldplot.php). 1B) Association plot of HDL-C at the ANGPTL3 locus, revealing no signiﬁcant
association. 1C) Association plot of TG at ANGPTL3 locus, showing rs2131925 as lead SNP. 1D) Association plot of LDL-C at ANGPTL3 locus, showing lead SNP as rs3850634 [1] (http://
csg.sph.umich.edu/locuszoom).
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2.2. Identiﬁcation of variants associated with ANGPTL3 mRNA
transcript levels
Gene expression and genotype data were obtained for 966 post-
mortem and surgical resection human liver samples from unrelated
European-American individuals [15]. Genotyping was carried out
using the Illumina 650Y BeadChip array, and Agilent human gene
expression arrays used to proﬁle 39,000 expression probes. Impu-
tation of genotypes not covered on the array was carried out as
previously described, and the full methods for this, and the pro-
cedures for colocalisation have been detailed previously [16].
2.3. Identiﬁcation of candidate functional SNPs using ENCODE
Published ENCODE annotations for the HepG2 liver cell line for
DNaseI-seq, FAIRE-seq, ChIP-seq (transcription factors and histone
methylation signatures H3K4me1 and H3K27Ac) were examined in
relation to variants associated with lipid biomarkers and ANGPTL3
transcript levels. Roadmap Epigenomics annotations for liver tissue
were examined for DNaseI-seq and histone modiﬁcations. SNPs
were identiﬁed which occurred within narrow peaks for DNaseI
hypersensitivity or within 500 bp of SPP narrow peaks for ChIP-seq
as previously described [17]. SNPs which were located close to
regulatory signatures (<500 bp were also included).
2.4. Tissue culture
HepG2 cells were cultured in high-glucose Dulbecco's modiﬁed
Eagle's medium (PAA, Austria) supplemented with 2 mM L-gluta-
mine and 10% foetal bovine serum (FBS; PAA). EBV-transformed
lymphoblast cell lines from the Centre d'Etude du Polymorphism
Humain (CEPH) panel (Coriell Cell Repositories), were cultured in
RPMI 1640 (PAA) with 2 mM L-glutamine and 15% foetal bovine
serum (PAA) at 37 C, 5% CO2. Cell viability was veriﬁed using the
ADAM-MC cell counter (Digital Bio), and minimum cell viability for
experiments was 99%. Cytokine stimulation was performed by
overnight incubation in serum-free media, followed by addition of
5 ng/ml IL-1b, two hours prior to cell ﬁxing.
2.5. In vitro analysis of DNA-protein interactions
Nuclear extracts were obtained from HepG2 cells using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce, USA)
as described in the manual, with the addition of Complete Protease
Inhibitor (Roche, UK) to buffers CER I and NER I. EMSA probes
were designed using 15 bp of genomic sequence on each side
of the candidate SNP, and reverse complement for each forward
strand was synthesised and annealed (sequences for all probes
available on request). Forward sequence for rs6690733: 50-
ATCAAAAGGGGGTAA(A/C)CACTACTACGTATAC and rs10889352: 50-
GCAAACAGAAAAAAA(T/C)ATAGTACTAGTAAAA-3’.
Probes were labelled using the Biotin 30-End DNA Labelling Kit
(Pierce, USA) as described in the manual, and complementary
labelled oligonucleotides annealed by heating to 95 C for 10 min,
followed by slow cooling (1 C/min to 30 C). Each binding re-
action consisted of 2 ml 10 binding buffer (100 mM Tris, 500 mM
KCl; pH 7.5), 1 mg p[dI-dC], 2 nmol biotin-labelled DNA, made to a
total of 20 ml with H2O, and incubated at 25 C for 30 min, followed
by the addition of 5 loading buffer. Samples were electrophoresed
on a 6% polyacrylamide gel for 150 min at 120 V. Transfer to nylon
membrane was achieved through Southern transfer and detected
using the Chemiluminescent Nucleic Acid Detection Module
(Pierce, USA).
2.6. In silico analysis of transcription factor binding
To determine which proteins may be interacting with EMSA
oligonucleotide probes, the MatInspector (Genomatix, Germany)
[18] database was examined using the Transcription Factor Binding
Sites (Weight matrices) library for general core promoter elements
and vertebrates matrix group. Core similarity (the proportion of
bases exactly matching the highest conserved positions of the
matrix) was set to 0.75. HaploReg v3was used as an addition source
for predicted SNP effects on transcription factor binding [17].
2.7. In vitro analysis of gene expression
For the putative ANGPTL3 regulatory elements surrounding the
SNPs of interest, oligonucleotides were designed with the addition
of BamHI and SalI restriction sites at the 5’- and 3’-ends and PCR
ampliﬁcation of homozygous wild-type individuals performed.
Primer sequences for cloning: rs6690733 - 50-GGGGCTACTCTT-
CAAATTCCCT-30 forward, 50-GGCCAGCTTCTCTCCCCTAT-30 reverse;
rs10889352 e 50-TGACACAGGCTAGGTGACAAA-30 forward, 50-
AGAAGCAGATGCCACCAAGG-30 reverse. PCR products were diges-
ted with BamHI and SalI, and ligated into the BamHI/SalI-linearized
pGL3 Promoter vector (Promega), downstream of the SV40 late
poly(A) signal. Allelic variants were created using the Site-Directed-
Mutagenesis kit (Invitrogen), the variant veriﬁed by sequencing
and insert digested and re-inserted into a fresh pGL3 vector. The
size of insert for rs6690733 was 249 bp and 192 bp for rs10889352.
HepG2 cells were seeded at 2.0 104/well in a 96 well plate and
grown to conﬂuence in high-glucose Dulbecco's modiﬁed Eagle's
medium (PAA, Austria) supplemented with 2 mM L-glutamine and
10% fetal bovine serum (FBS). Cells were transfected with 250 ng
pGL3 reporter construct with 10 ng pRLTK as a transfection control.
Transfection was carried out using Opti-Mem serum-free media
(Sigma, Dorset, UK) and Lipofectamine 2000 (Invitrogen, Paisley,
UK) as described in the manual. Media was replaced 24 h following
transfection, with serum-containing media, and the cells left for 2
days before harvesting. Cells were lysed using Passive Lysis Buffer
(Promega, Southampton, UK) and luciferase expression was deter-
mined using the Dual Luciferase Reporter Assay System (Promega,
Southampton, UK), and measured in the Tropix TR717 Microplate
Luminometer (PE Applied Biosystems, UK). Luciferase activity was
determined as the mean of 12 transfections with the assay per-
formed in triplicate.
2.8. Allele-speciﬁc FAIRE
The methodology for allele-speciﬁc FAIRE used for this study is
described elsewhere [19]. Brieﬂy, 20 unrelated lymphoblast cell
lines of European origin (Coriell Repositories) were ﬁxed in the log-
phase of growth, and the chromatin extracted. Following sonicat-
ion, one portion of chromatinwas reverse-crosslinked and puriﬁed,
the other underwent FAIRE enrichment using phenol:-
chloroform:isoamyl alcohol. Following reversal of crosslinks and
DNA puriﬁcation, all samples were genotyped using the Illumina
Metabochip array. Identiﬁcation of heterozygous individuals at
each allele was determined using the B allele frequency (BAF) from
the samples not enriched by FAIRE, and the BAF for these in-
dividuals compared to that from the FAIRE-treated samples. For
rs6690733, which was not present on the Metabochip array, a
custom KASPar (KBioscience) genotyping assay was created to
determine the allelic imbalance in heterozygotes from extrapola-
tion from a standard curve, and this data was analysed in the same
manner as with the Metabochip-derived genotype data (KASPar
probes available on request).
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2.9. Statistical analysis
Luciferase expression was normalised to the pRLTK control
vector, and a 2-sided t-test performed between each run of 12
samples. Assays were performed in triplicate. Analysis of FAIRE-gen
was performed using a paired t-test between the BAF from SNPs of
all heterozygous individuals, comparing non-FAIRE vs FAIRE-
treated chromatin. Imputation of genotypes not covered on the
array was carried out as described [16] using EUR reference hap-
lotypes available from the 1000 Genomes Project. eQTL analysis
was run by ﬁtting a linear regression between expression of the
gene and all SNPs between 200 kilobases upstream and down-
stream from the probe. Colocalisation analysis between eQTL and
lipid biomarkers uses summary statistics downloaded from a
publicly available meta-analysis (http://www.sph.umich.edu/csg/
abecasis/public/lipids2010/) and the statistical methodology is
described in full in [16]. A posterior probability >75% was consid-
ered as strong evidence for colocalisation.
3. Results
3.1. Selection of SNPs associated with lipid biomarkers
To identify the pool of variants most likely to contain the
functional variant/s responsible for TG and LDL-C plasma levels at
the ANGPTL3 locus, all variants from the 1000 Genomes Project [9]
in strong LD (r2 > 0.8) with the GWAS lead SNPs (rs2131925 and
rs3850634, respectively) were identiﬁed, providing 202 SNPs
(Supplementary Table 1). Additionally, meta-analysis data from
>100,000 individuals with lipid measurements was examined [1],
and association at the ANGPTL3 locus with TG and LDL-C was
determined. From this dataset, 151 SNPs reaching genome-wide
signiﬁcance (p < 5  108) were selected. All 106 LDL-C associ-
ated SNPs were present within the subset associated with TG
(Supplementary Fig. 1). Since the associated polymorphisms are all
non-coding variants and therefore likely to be affecting gene
expression levels, liver eQTLs for ANGPTL3were examined from 966
liver samples, including imputed SNPs from 1KGP not directly
genotyped. This data corroborated the association of epidemio-
logical data for lipid levels with ANGPTL3 transcript levels
(Supplementary Figs. 2 and 3). In total, 253 SNPs were identiﬁed to
show either genome-wide association to a lipid trait or a liver eQTL
for ANGPTL3 within the 0.8 r2 cut-off with the TG lead SNP from
GWAS, rs2131925 (Supplementary Table 1). Interestingly, it was
observed that DOCK7 transcript levels are also affected by the same
variants that affect ANGPTL3 expression.
3.2. Colocalisation of lipid associations and liver eQTLs at the
ANGPTL3 locus
To determine if the association with TG and LDL-C levels at the
ANGPTL3 locus shared a causal variant/s with liver ANGPTL3 mRNA
expression, a Bayesian test to examine colocalisation between pairs
of traits was performed (procedure detailed in [16]). Summary
statistics from associations with TG and LDL-C were derived from
the lipid meta-analysis data used to select ANGPTL3 variants [1],
and the 966-sample liver expression dataset described previously
was used for eQTL analysis, with imputation used to detect variants
not directly genotyped. The data demonstrated that both TG (pos-
terior probability 92.4%) and LDL-C (posterior probability 90.6%)
colocalise with ANGPTL3 expression, indicating a shared causal
variant or variants (Supplementary Fig. 2). Due to the very strong
LD at the region, however, colocalisation did not reduce the pool of
potential causal variants, and all 253 SNPswere included for further
examination to assess functional potential.
3.3. Functional assessment of potential regulatory ANGPTL3 SNPs
Since variants at the ANGPTL3 locus that determine TG and LDL-
C levels colocalise with eQTL markers for ANGPTL3 transcript levels,
a common variant (or variants) affecting gene regulatory processes
is likely to be responsible for both associations. The potential for
this selection of 253 variants to affect gene regulationwas assessed
by examining data from the ENCODE Project and Roadmap Epi-
genomics 14 13. Since none of these variants occur within ANGPTL3
coding regions, 50 or 3’ UTR, or predicted splice sites, allele-speciﬁc
regulation is likely to be through effects on promoter, enhancer or
silencer elements, rather than effects on mRNA stability. Since the
variants are also associated with DOCK7 transcript levels, a com-
mon enhancer/silencer element is more likely to be affected than
an ANGPTL3 promoter element. To identify variants that may affect
such regulatory elements, ENCODE and Roadmap Epigenomics
datasets were searched for universal signatures of regulatory po-
tential, including DNaseI hypersensitivity (DHS) peaks, histone
modiﬁcations and FAIRE-seq peaks, and also for transcription factor
binding sites. Variants present within, or close (500 bp) to these
signatures were also selected for further analysis. 33 SNPs were
present directly within an annotated regulatory region in liver cells,
and 13 were present close to a regulatory annotation and were
included for further analysis due to possible longer-range regula-
tory roles (Table 1).
3.4. Allele-speciﬁc protein-binding effects of SNPs within regulatory
regions
For a non-coding functional variant to affect gene expression, it
would be expected to alter binding afﬁnities of transcription factor/
s. To assess the potential for each of the 46 lipid-associated variants
from ENCODE/Roadmap Epigenomics-derived regulatory regions to
affect the interaction of DNA-binding proteins, electrophoretic
mobility shift assays (EMSAs) were performed for each of the al-
leles, using biotin-labelled double-stranded oligonucleotide probes
comprising 30bp genomic sequence surrounding each variant, with
the variant located directly at the centre of each probe. Each
oligonucleotide probe was incubated with a HepG2 liver nuclear
extract, and the resulting complexes run on a polyacrylamide gel.
From a pool of 46 SNPs, 44 either did not result in transcription
factor binding from either allele, or both alleles resulted in identical
binding of equal intensity, with the binding site likely to be located
outside of the polymorphic site. Two variants demonstrated repli-
cated allele-speciﬁc binding to the liver nuclear extract, rs6690733
and rs10889352, indicating changes in transcription factor binding
potential, and a possible regulatory role (Fig. 2). Interestingly both
variants appear to show multiple proteins bound to the oligonu-
cleotide probes, suggesting a complex means of allele-speciﬁc
regulation. Replication with a Huh7 nuclear extract demonstrated
identical binding patterns to HepG2 nuclear extract (data not
shown) indicating a factor common to hepatic cells.
Examination of predicted changes to transcription factor bind-
ing based on each allele was examined using two related tools:
MatInspector [18] and HaploReg v2 17, which use extensive libraries
of matrix descriptions for transcription factor binding sites to
identify matches in DNA sequences. Both variants are predicted to
alter binding sites for a number of transcription factors (Table 2).
Although the two algorithms produced differing results, certain
similarities were evident, such as a forkhead box protein with
rs10889352 C, and promyelocytic leukaemia zinc ﬁnger binding
with rs10889352 T. ExaminingMatInspector or HaploReg v2 results
in isolation, there was a similarity in the number of predicted
binding factors for each allele as seen in EMSA analysis. To deter-
mine if the in silico predicted binding was borne out in vivo,
F. Oldoni et al. / Atherosclerosis 246 (2016) 193e201196
competitor assays were performed using a panel of unlabelled
consensus sequences for 80 transcription factors, including 70well-
characterised transcription factors, and those predicted to be
altered in silico [20]. This analysis, however, failed to verify the
binding of predicted transcription factors or identify additional
factors (data not shown), indicating a lack of reliability from pre-
diction algorithms, or tissue-speciﬁc effects.
3.5. In vitro analysis of gene expression
The two SNPs associated with TG levels, ANGPTL3 transcription
and allele-speciﬁc DNA-protein interactions are strong candidates
for functionality. To examine the effects of these two poly-
morphisms on gene expression, luciferase reporter assays were
performed by designing reporter constructs containing the
genomic region surrounding each SNP (200e250 bp) downstream
of luc reporter gene (acting as a putative enhancer), driving the
SV40 promoter in the pGL3 promoter vector. Constructs were
transiently transfected into the HepG2 cell line and luciferase ac-
tivity measured.
Both rs6690733 and rs10889352 showed allele-speciﬁc effects
on reporter gene expression, with each demonstrating modest re-
ductions (~10% reduction from each variant; p < 1  1010) in gene
expression for the minor alleles (Fig. 3). Interestingly, both poly-
morphisms appear to act as silencers in this gene expressionmodel.
3.6. In vivo analysis of allele-speciﬁc effects on chromatin structure
Variants that affect gene transcription which are not located
either within a transcription factor protein-coding sequence or
regulatory RNA-coding sequence (e.g. miRNA), as is the case at the
ANGPTL3 locus, are likely to be functioning through alteration of
DNA-protein interactions at promoter, enhancer or silencer ele-
ments. These interactions can either result in, or be altered by,
disruption to the local chromatin structure [19]. To assess whether
the two potentially functional variants at the ANGPTL3 locus may
have an effect on chromatin structure and to substantiate in vitro
functionality in vivo, allele-speciﬁc formaldehyde-assisted-isola-
tion-of-regulatory-elements (FAIRE) was performed. The allelic
imbalance was assessed from heterozygotes following FAIRE-
Table 1
Variants located within ENCODE-derived gene regulatory sites.
SNP Promoter histone signature Enhancer histone signature DNaseI hypersensitivity Proteins bound
rs10889356 X X X
rs9436661 X
rs1168046 X
rs10789117 X
rs10889344 X
rs11207979 X
rs1168047 X
rs12029068 X
rs638714 X
rs6690733 X
rs9436221 X
rs9436222 X
rs4587594 X
rs6678483 X
rs11207997 X
rs12090886 X
rs1168045 X
rs1627591 X
rs10889337 X
rs10493322 X X
rs1168114 X X X
rs1168113 X X X
rs12136083 X
rs6679002 X
rs12130333 X
rs10889377 X
rs17123817 X
rs10889378 X
rs13375691 X X
rs646179 X X
rs9436223 X
rs631106 X X
rs626787 X
rs10889347 (X)
rs6587980 (X)
rs1184547 (X)
rs10157265 (X)
rs1168015 (X) (X)
rs12062275 (X)
rs10889336 (X) (X)
rs1168042 (X) (X)
rs12037659 (X)
rs11207976 (X)
rs1184865 (X)
rs11207992 (X)
rs10889352 (X)
X ¼ SNP located within regulatory site.
(X) ¼ SNP located close to regulatory site.
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enrichment for open chromatin, compared to non-enriched chro-
matin, using lymphoblast chromatin samples from 20 unrelated
individuals.
Interestingly, rs10889352 T > C did indeed demonstrate a robust
allele-speciﬁc effect on chromatin accessibility (20.4% enrichment
of T allele from 10 FAIRE-treated heterozygotes compared to T
allele-enrichment from non-treated cells, p ¼ 0.002), suggesting
that the T allele allows for an increased regulatory potential than
the C allele. This data ﬁts with the increased binding of nuclear
proteins to the T allele, and higher expression levels in reporter
assay, along with the T allele associated with higher ANGPTL3
transcript levels. The other potentially functional variant at the
locus, rs6690733, however did not demonstrate effects on chro-
matin accessibility (p ¼ 0.53), and is therefore a less plausible ca-
sual candidate SNP.
Since expression of the ANGPTL-family respond to inﬂamma-
tory stimuli [21], allele-speciﬁc FAIRE was repeated with
lymphoblast cells treated with the inﬂammatory cytokine IL-1b
prior to the ﬁxing of cells for FAIRE, with the hypothesis that
transcription factors from inﬂammatory pathways may exacerbate
allele-speciﬁc effects on chromatin accessibility. Upon stimulation,
rs10889352 showed a similar effect (25.5% enrichment of T allele
following FAIRE) and signiﬁcance level (p ¼ 0.0019), replicating the
original effects, suggesting in this case that inﬂammation does not
interact with the functional variant.
4. Discussion
Identiﬁcation of functional variants from GWAS can be a labo-
rious process with large blocks of LD surrounding the lead SNP
often resulting in unfeasible numbers of variants to examine in the
laboratory. The sequential methodology described here outlines a
series of in silico and laboratory-based assays to localise functional
loci at non-coding regions of the genome, using the ANGPTL3 locus
and its association with TG and LDL-C as an example
(Supplementary Fig. 4). Having deﬁned the set of potentially
functional SNPs using both epidemiological data and eQTL data
from the relevant tissue (liver), data from the ENCODE Project and
Roadmap Epigenomics were examined in liver cells to identify re-
gions of regulatory potential surrounding each variant, reducing
the number of potentially functional variants to 46. Three com-
plementary laboratory methods were employed to examine the
effect of this reduced set of variants on regulatory potential: EMSA,
a relatively inexpensive and quick method to identify the effect of
variants on DNA-protein interactions; luciferase reporter assay to
examine the role of these variants in gene expression; and FAIRE-
Fig. 2. Allele-speciﬁc effects on DNA-protein interactions. A HepG2 liver nuclear
extract was mixed with allele-speciﬁc sequences for all potential regulatory variants
from ENCODE analysis and allele-speciﬁc FAIRE signals. Binding differences were
observed from two variants: rs6690733 and from rs10889352. Arrows indicate where a
binding difference was identiﬁed between alleles, suggesting a potential effect on gene
regulation.
Table 2
Comparison of predicted transcription factor binding to putative functional ANGPTL3 variants using MatInspector and HaploReg v2 databases.
SNP Allele MatInspector predicted transcription factor binding HaploReg v2 predicted transcription factor binding
rs10889352 C Forkhead family Forkhead Box Protein D3
rs10889352 T NKX-homeodomain factors, promyelocytic leukaemia zinc-ﬁnger Ecotropic viral integration site 1/4, Glucocorticoid receptor,
promyelocytic leukaemia zinc-ﬁnger, p300
rs6690733 A Barbiturate-inducible element box from pro þ eukaryotic genes, forkhead family,
GLI zinc ﬁnger family, pleomorphic adenoma gene
rs6690733 C Barbiturate-inducible element box from pro þ eukaryotic genes, hepatic nuclear
factor 1, pleomorphic adenoma gene
forkhead box D3, forkhead box O4
Fig. 3. Representative luciferase reporter assays for the two SNPs showing relative
allele-speciﬁc effects on DNA-protein interactions compared to pGL3 promoter vector.
Diagonal hatched columns represent the alleles associated with increased gene
expression. Error bars represent standard error, *** ¼ p < 0.001. Assay was repeated
three times with 12 wells containing each vector per assay.
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gen [19], to conﬁrm an in vivo role of these variants on chromatin
accessibility and therefore regulatory potential.
Allele-speciﬁc effects on DNA-protein interactions were
observed only for two SNPs (rs6690733 and rs10889352) from of
the 46 variants selected from ENCODE, and effects of this
manageable number of variants on gene expressionwere examined
by luciferase reporter assays. Both variants also showed allele-
speciﬁc effects on gene expression, with each allele that showed
increased expression levels also associated with increases in
ANGPTL3 transcript expression. Examining in vivo effects on chro-
matin accessibility, only one of the two variants, rs10889352,
demonstrated allele-speciﬁc effects with the T allele associated
with a 20% increase in chromatin accessibility. The rs10889352 T
allele may be associated with chromatin accessibility by altering
the stability of the nucleosome complex directly from alterations in
the DNA sequence, or, more likely from EMSA evidence, by altering
the afﬁnity of transcription factors which would in turn, alter
chromatin dynamics.
Despite >200 variants in very strong LD with the lead SNP, only
one SNP demonstrated likely functionality based on all bioinfor-
matics, in vivo and in vitro analyses. The variant rs10889352 is
located outside of the coding region for ANGPTL3, within an intron
of DOCK7 (Supplementary Fig. 5), and close to accessible chromatin
determined by FAIRE-seq in HepG2 cells (Supplementary Fig. 6).
Several transcription factor binding motifs are predicted to be
altered by this variant: EVI1, FOXD3, GR, PLZF and p300 (Table 2).
Higher afﬁnity for these factors are predicted for the T allele, which
supports the increased protein-DNA interactions for this allele
observed in EMSA, and increased reporter gene expression. We
could not, however, conﬁrm the identity of these DNA-binding
factors, despite assaying for those predicted to bind. This does not
necessarily limit the ability to assign functionality to this variant,
but does highlight the limitations of using in silico tools to correctly
predict transcription factor binding. It does, however, restrict the
use of chromatin immunoprecipitation to demonstrate in vivo in-
teractions, another technique that would help characterise func-
tional variants and determine the precise mechanism of action.
The study described here utilises multiple lines of evidence to
demonstrate SNP functionality. Where it is necessary to isolate
individual SNPs for analysis, methods such as EMSA and reporter
assays are important, but take no account of chromatin accessi-
bility, requiring such information from sources such as ENCODE and
Roadmap Epigenomics. FAIRE-gen largely overcomes this weak-
ness, with long-range LD no longer a limiting factor. A potential
limitation with the assay described here is the use of allele-speciﬁc
FAIRE data from lymphoblasts for examining traits seen in the liver.
However, although absolute levels of accessible chromatin are
tissue-speciﬁc, and largely colocalise with tissue-speciﬁc tran-
scription factor binding sites [22], evidence frommultiple cell lines
indicates a correlation of allele-speciﬁc effects on accessible chro-
matin between cell lines [23], providing validity to such analysis.
The use of cell lines rather than primary hepatocytes adds one
limitation to in vitro analysis, and although we replicated DNA-
protein interactions with an additional liver cell line, primary
hepatoctyes may provide a different result.
This study demonstrates the complexity of identiﬁcation of SNP
functionality in regions where strong LD is present, and where
several variants in near-complete LD may be having additive/
opposite effects. Such information will be important when exam-
ining loci in populations with different LD structures, where
knowledge of the functional variant will be able to improve the risk
prediction for individuals in these populations compared using a
lead tag SNP derived from another population. The methodology
described here provides an outline to localise potentially causal
regulatory variants based on the use of complementary tools.
Reducing the number of functional variants at GWAS loci will allow
for the emerging genome-editing techniques such as transcription
activator-like effector nucleases [24] and CRISPR/Cas9 [25] to
conﬁrm causality, with the ability to examine effects of single
variants in cell-based models on gene expression. As the regulome
continues to be examined using increasing numbers of cell lines/
tissues, and annotations reﬁned with more sophisticated tools,
identiﬁcation of functional elements will signiﬁcantly improve our
ability to predict likely effects of non-coding genetic variants. We
have demonstrated here how such annotations can currently help
identify potentially functional variants associated with GWAS traits
by examining data from primary hepatocytes and HepG2 cells to
deﬁne regulatory elements in liver cells. The data from these two
cell types are likely to cover the majority of regulatory elements,
but with further genome-wide analyses, such as ChIP-seq for
transcription factors in primary hepatocytes, additional regulatory
regions may be discovered at the ANGPTL3 locus.
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